华润双鹤：氯化钾注射液获批

Core Viewpoint - China Resources Double Crane announced that its wholly-owned subsidiary, Anhui Double Crane Pharmaceutical Co., Ltd., received the approval notice for the supplementary application of potassium chloride injection from the National Medical Products Administration [1] Group 1: Product Approval - The approved drug, potassium chloride injection, is used for the treatment and prevention of hypokalemia [1] - The existing specification of potassium chloride injection is 10ml:1g, and the new approval adds a 10ml:1.5g specification [1] Group 2: Financial Investment - The total R&D investment for the potassium chloride injection amounts to 1.6109 million RMB [1] Group 3: Market Potential - The global sales forecast for potassium chloride injection in 2024 is 223 million USD [1] - The total sales in the domestic medical and retail market for potassium chloride injection is projected to be 617 million RMB [1] - The expected sales revenue for the company's potassium chloride injection in 2024 is 960,000 RMB [1]